Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024
01 März 2024 - 1:00PM
Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company
leveraging its proprietary DNAbilize® antisense RNAi nanoparticle
technology to develop a portfolio of targeted nucleic acid cancer
drugs, today announced that it will host a live conference call and
audio webcast on Friday, March 8, 2024 at 8:30 a.m. ET to report
financial results for the fourth quarter and full year ended
December 31, 2023 and to provide a business overview.
To access the live conference call, please call (833) 630-1956
(domestic) or (412) 317-1837 (international) at least five minutes
prior to the start time. A live audio webcast of the call will also
be available on the Presentations section of the Company’s website,
www.biopathholdings.com. An archived webcast will be available on
the Bio-Path website approximately two hours after the event.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a
novel technology that has yielded a pipeline of RNAi nanoparticle
drugs that can be administered with a simple intravenous
transfusion. Bio-Path’s drug candidate, Liposomal Bcl-2, (BP1002,
targeting the Bcl-2 protein responsible for driving cell survival
in up to 60% of all cancers) has announced the enrollment and
dosing of the first patient in a Phase 1/1b clinical trial.
Bio-Path’s drug candidate, Liposomal STAT3 (BP1003, targeting the
STAT3 protein) has one additional IND enabling study to complete
before the Company may file an IND application and initiate the
first-in-humans Phase 1 study in patients with refractory,
metastatic solid tumors. In addition, Bio-Path has a modified
product named BP1001-A (prexigebersen with enhanced nanoparticle
properties) which has shown to enhance efficacy in preclinical
solid tumor models and is currently in a Phase 1/1b clinical trial
conducted at several leading cancer centers in the United
States.
For more information, please visit the Company's website at
http://www.biopathholdings.com.
Contact Information:
Investors
Will O’ConnorStern Investor Relations
212-362-1200will@sternir.com
Doug Morris Investor Relations Bio-Path Holdings, Inc.
832-742-1369
Bio Path (NASDAQ:BPTH)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Bio Path (NASDAQ:BPTH)
Historical Stock Chart
Von Mai 2023 bis Mai 2024